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Abstract 
Background: Influenza viruses are divided into three types, A, B, and C. Human influenza A and B viruses can cause 
seasonal epidemics, but influenza C causes only a mild respiratory illness. Influenza A virus can infect various host 
species. In 2013, human-infectious avian influenza A (H7N9) was first reported in China. By the second week of 2014, 
there were 210 laboratory-confirmed human cases in the country, and the mortality rate eventually reached 22 %. 
Rapid and accurate diagnosis of influenza viruses is important for clinical management and epidemiology.
Methods: In this assay, a cost-effective chemiluminescence (CL) detection oligonucleotide microarray was devel-
oped to genotype and detect avian influenza A (H7N9), avian influenza A (H5N1), 2009 influenza A (H1N1), seasonal 
influenza A (H1N1), and seasonal influenza A (H3N2). Influenza A viruses and influenza B viruses were also generally 
detected using this microarray.
Results: The results of detection of 40 cultivated influenza virus strains showed that the microarray was able to distin-
guish the subtypes of these influenza viruses very well. The microarray possessed similar or 10 fold higher limit of 
detection than the real-time RT-PCR method. Sixty-six clinical swab samples were detected using this microarray and 
verified with real time RT-PCR to evaluate the efficiency of this microarray for clinical testing.
Conclusions: A reliable CL detection oligonucleotide microarray had been developed to genotype and detected 
these influenza viruses.
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Background
Influenza viruses are divided into three types, A, B, and 
C (WHO 1980). Human influenza A and B viruses always 
cause seasonal epidemics, but influenza C causes only a 
mild respiratory illness. Influenza A viruses are further 
divided into various subtypes based on hemagglutinin 
(HA) and neuraminidase (NA). Currently, seventeen 
serotypes of hemagglutinin (H1–H17) and ten serotypes 
of neuraminidase (N1–N10) of influenza A virus have 
been identified in mammalian and avian species (Fouch-
ier et  al. 2005; Zhu et  al. 2013). Influenza B viruses are 
broken down into B/Yamagata and B/Victoria lineages 
(Zhang et al. 2012). They are not divided into subtypes.
Influenza A virus can infect various host species. The 
greatest diversity of subtypes is found in wildfowl. The 
ease with which influenza A can recombine causes viral 
epidemics to spread across different species (dos Reis 
et  al. 2011). There have been several influenza A pan-
demics during the past 100  years: influenza A (H1N1) 
caused Spanish flu in 1918, causing 50 million deaths 
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(Taubenberger and Morens 2006). Another influenza A 
(H2N2), caused Asian flu in 1957, with one million deaths 
(Xu et al. 2010). Influenza A (H3N2) caused Hong Kong 
flu in 1968, with another one million deaths (Viboud et al. 
2005). A novel influenza A first noted in 2009, H1N1 
caused the swine flu in 2009, with 0.28 million deaths 
(Dawood et  al. 2012). There have also been small-scale 
epidemics, such as the avian influenza virus A (H5N1) 
outbreak in Hong Kong in 1997, in which 18 individuals 
were infected and 6 died (WHO 2004). In addition to the 
avian influenza virus A H5N1, highly pathogenic avian 
influenza virus A H5N2 (Yang et  al. 2015; Zhan et  al. 
2012), avian influenza virus A H5N5 (Gu et  al. 2011), 
H5N6 (Li et al. 2016; Qi et al. 2014), H5N8 (Wang et al. 
2016; Zhao et al. 2013), and H5N9 (Yu et al. 2015) have 
also been isolated or confirmed from avian, mice, dog, 
or humans in China since 2000. It is noteworthy that 
the first human avian influenza A H5N6 infections were 
reported in Sichuan province (Nations and F.a.A.O.o.t.U. 
2014) and caused 14 laboratory-confirmed human 
cases (including six deaths) by 9 May 2016 (Organiza-
tion 2016). In 2013, human-infectious avian influenza 
A (H7N9) was reported in China (Gao et al. 2013b). By 
the second week of March 2016, there had been 752 
laboratory-confirmed human cases in China, including 
at least 295 deaths (WHO 2016a, b). The clinical mani-
festations, severity, and mortality rates of human-infec-
tious avian influenza A (H7N9) were similar to those of 
avian influenza A (H5N1) and 2009 influenza A (H1N1) 
but quite different from seasonal influenza (Gao et  al. 
2013a). Many studies have shown that it is more effective 
to reduce the severity of the infection when administra-
tion of NA inhibitor within 48 h of the onset of influenza 
symptoms than after 48  h (Hayden et  al. 1997; McGeer 
et  al. 2007; Monto et  al. 1999). For these reasons, rapid 
and accurate diagnosis influenza viruses are important to 
clinical management and epidemiological.
Some molecular diagnostic technologies have been 
used to diagnose and subtype influenza viruses: anti-
gens and antibody detection (Duman et  al. 2013; He 
et  al. 2013), real-time PCR (Choi et  al. 2013; Dawood 
et  al. 2009; Gao et  al. 2013a; Hackett et  al. 2014; Poon 
et  al. 2009; Templeton et  al. 2004), sequencing (Deng 
et al. 2011; Ghedin et al. 2011; Rutvisuttinunt et al. 2013), 
and microarray (Gall et  al. 2009; Han et  al. 2008; Heil 
et  al. 2010; Ryabinin et al. 2011). In the assay described 
here, a chemiluminescence (CL) detection oligonucleo-
tide microarray was developed and used to detect avian 
influenza A (H7N9), avian influenza A (H5N1), 2009 
influenza A (H1N1), seasonal influenza A (H1N1), and 
seasonal influenza A (H3N2) by genotyping. The micro-
array also detected influenza A and influenza B viruses in 
all cases. The efficiency of this CL detection strategy was 
investigated in actual samples and the results were com-
pared to those of real-time PCR methods.
Methods
Specimen collection and processing
The six clinically isolated strains of avian influenza A 
(H7N9) were obtained from the Centers for Disease Con-
trol (CDC) of Zhejiang Province. The other cultivated 
influenza virus strains were obtained from the National 
Institutes for Food and Drug Control. Clinical throat 
swab samples were collected from patients suspected of 
having infected influenza in the 307th Hospital of the 
Chinese People’s Liberation Army for whom it was not 
possible to determine whether they had taken medica-
tion. Non-influenza respiratory viruses were identi-
fied and obtained from the National Institute for Viral 
Disease Control and Prevention and the 302nd Hos-
pital of the Chinese People’s Liberation Army. Lysate 
had already been added to all these viral samples before 
they were acquired for the present study. Total RNAs 
were extracted using the TIANamp Virus RNA Kit as 
described in the manufacturer’s protocol (TIANGEN 
Biotech Beijing Co., Ltd.) and stored at −70 °C until use.
Primer and probe design
HA and NA gene FASTA sequences of avian influenza 
H7N9 virus, NA gene FASTA sequences of avian influ-
enza H5N1 virus, 2009 influenza A (H1N1), seasonal 
influenza A (H1N1), influenza A (H3N2), matrix protein 
(M) gene of influenza A virus, and nonstructural protein 
(NS) gene of influenza B virus were downloaded from 
NCBI’s influenza nucleotide database. The sequences 
were then aligned using AlignX (a component of the Vec-
tor NTI Advance 10.3.0) to compare homology. Geno-
typing primers for these subtypes of influenza A were 
designed using Primer Premier 5 (PREMIER Biosoft 
International, USA) and they served as the consensus 
sequences of the HA and NA genes. Universal primers for 
influenza A virus and influenza B virus were designed and 
served as the consensus sequences of the relatively well-
conserved M and NS genes. Microarray probes ranging 
from 20 to 40 nt were designed to detect influenza A virus 
generally, influenza B virus generally, and these subtypes 
of influenza A virus. Internal standard primers and probes 
based on the sequences of Homo sapiens ribonuclease P 
were designed to monitor specimen extraction, RT-PCR 
amplification, and microarray hybridization. This marker 
has been described as a reliable internal positive control 
marker in several publications (Dare et al. 2016; Fan et al. 
2014). All the primers and probes were confirmed using 
BLAST program of NCBI and then synthesized using 
Sangon Biotech Co., Ltd. (Shanghai). The primers and 
probes are shown in Tables 1 and 2.
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Microarray preparation
A repeat sequence of (T)12 with an amino-labeled 3′-end 
was connected to the 3′-end of all the probes so that it 
could be fixed to the aldehyde-chip surface.
A repeat sequence of (T)20 with a biotin-labeled 5′-end 
and an amino-labeled 3′-end served as a quality control 
probe. The probes were used at 50  μM final concentra-
tion. They were spotted and repeated three times in the 
Table 1 Primer sequences for microarray
a The numbers are NCBI accession codes
Primer Sequence (5′–3′) Target Gene Location Referencea
NA-1Sa GTTCTATGCTCTCAGCCAAGG H7N9 NA 378–398 CY146910
NA9r-B-4 GCATTGTTGTTTGGTCCTGATATAC H7N9 NA 569–593 CY146910
H7F1 AGACCTCGGTCAATGYGG H7N9 HA 201–218 CY146908
H7R2-B TTCACGAATTTCCCAGGATAACA H7N9 HA 313–335 CY146908
NF11 CAAGAGTCTGAATGTGCATG H5N1 NA 699–718 AM183680
NR22B GGATCCCAAATCATTTCAAA H5N1 NA 1134–1153 AM183680
F7 GTGTGTGCAGGGATAACTGG PH1N1 NA 889–908 CY081570
R4aB ATTAGGGCGTGGATTGTCTC PH1N1 NA 988–1007 CY081570
NF12 CAAGAGTCTGAATGTGTCTG H1N1 NA 699–718 AJ006954
NR21B GGATCCCAAATCATCTCAAA H1N1 NA 1131–1150 AJ006954
NF5 CTGACCAACACCACCATA H3N2 NA 221–238 CY091836
NR5B CATCAATAGGGTCCGATA H3N2 NA 482–499 CY091836
MF2 GGCCCCCTCAAAGCCGAGAT Influenza A M 77–96 HQ664927
MR2B CAAAGCGTCTACGCTGCAGT Influenza A M 244–263 HQ664927
FBF1 ATGGCCATCGGATCCTCAACTCACTC Influenza B NS 737–762 CY099917
FBR1B TCATGTCAGCTATTATGGAGCTGTT Influenza B NS 956–980 CY099917
RP-F4 TGGGATCATGTTAAGTAGAAGTAGC Human RNase P 1821–1854 NM_006413
RP-R4B CTCCATTGTTTTAGAGCCCTTAC Human RNase P 1882–1904 NM_006413
RP-F1 TGCGGGTTGGAGAAAATACA Human RNase P 1964–1983 NM_006413
RP-R1B GGAGGCTGAGGCAGGAGAAT Human RNase P 2086–2105 NM_006413
RP-F AGATTTGGACCTGCGAGCG Human RNase P 50–68 NM_006413
RP-RB GAGCGGCTGTCTCCACAAGT Human RNase P 95–114 NM_006413
Table 2 Probe sequences for microarray
a The numbers are NCBI accession codes
b A repeat sequence of (T)12 with an amino-labeled 3′-end was connected to the 3′-end of all the probes
c A repeat sequence of (T)20 with an amino-labeled 3′-end and biotin-labeled 5′-end was used for quality control during microarray
Probe Sequence (5′–3′)b Target Gene Location Referencea
H7-a ACTGGACCACCCCAATGTGACCAATTCCTAGAATTT H7N9 HA 235–270 CY146908
H7-b ATAGGACCTCCCCAATGCGATCAATTTCTGGAGTTT H7N9 HA 235–270 CY146908
N9 GGAAACACTCAAACGGAACAATACACGATAGGTCCCAGTA H7N9 NA 413–452 CY146910
PH1N1 GGCTCGAATCGACCGTGGGT PH1N1 NA 912–931 CY081570
H1N1 CAATCCAGTGACTGTTGATGGAGCAA H1N1 NA 1025–1050 AJ006954
H3N2 TAACATTACAGGATTTGCACCTTTTTC H3N2 NA 295–321 CY091836
H5N1-a CAAATAGGCCATGGGTATCTTTCAATC H5N1 NA 856–882 AM183680
H5N1-b GTGTCCCCTAACGGGGCATATGGGG H5N1 NA 972–996 AM183680
A CTCATGGAATGGCTAAAGACAAGACCAA Influenza A M 149–176 HQ664927
B AATGAAGGACATTCAAAGCCAATTCGAGCAGCTGAAACTGCG Influenza B NS 775–816 CY099917
RP-P TTCTGACCTGAAGGCTCTGCGCGCG Human RNase P 71–95 NM_006413
RP-P1 CATGAACCCAGGAGGCGGAGCTTGC Human RNase P 1995–2019 NM_006413
PR-P4 ACATGCATTTATGCAATATTAATGT Human RNase P 1859–1883 NM_006413
(T)20 TTTTTTTTTTTTTTTTTTTT Quality control
c
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vertical direction on the surface of the aldehyde-chip 
using uniform proportional printing buffer as described 
in previous studies (Zhang et al. 2013). The quality con-
trol probes were spotted and repeated seven times in the 
horizontal direction (Fig. 1b).
RT‑PCR amplification
The primers were used in three different RT-PCR sys-
tems. Each RT-PCR was performed in a 25  μl reaction 
volume containing 12.5 μl of 2× One Step Buffer, 1.0 μl 
of PrimeScript One-step Enzyme Mix (DRR055A, Takara 
Biotechnology (Dalian) Co., Ltd.), 5 μl of total RNA tem-
plate, and specific primer mix. RT-PCR system A ampli-
fied novel avian influenza A (H7N9) and avian influenza 
A (H5N1). It contained primer H7F1 0.16  μM, H7R2-
B 0.8  μM, NA-1Sa 0.12  μM, NA9r-B-4 0.6  μM, NF11 
0.1  μM, NR22B 0.5  μM, RP-F4 0.08  μM, and RP-R4 
0.4  μM. RT-PCR system B amplified 2009 influenza A 
(H1N1), seasonal influenza A (H1N1), and influenza A 
(H3N2). It contained primer F7 0.1  μM, R4aB 0.5  μM, 
NF5 0.1 μM, NR5B 0.5 μM, NF12 0.1 μM, NR21B 0.5 μM, 
RP-F1 0.1  μM, and RP-R1B 0.5  μM. RT-PCR system C 
amplified influenza A and B viruses. It contained primer 
MF2 0.1 μM, MR2B 0.5 μM, FBF1 0.1 μM, FBR1B 0.5 μM, 
PR-F 0.05 μM, and RP-RB 0.25 μM. All the three systems 
contained a pair of primers that could amplify the gene of 
Homo sapiens ribonuclease P, which served as an inter-
nal standard. Amplifications were performed on a Veriti 
Fig. 1 Microarray layout and CL detection results of parts of cultivated influenza viruses. a Working principle of this CL imaging DNA hybridization 
method. Steps 1–2 showed that capture probes were fixed to the aldehyde-chip surface. Step 3 showed that the denatured RT-PCR products were 
hybridized on the capture-chip. Steps 4–5 showed the CL detection principle. Biotin was incorporated into reverse strand on the RT-PCR ampli-
fication. Then, HRP modified streptavidin was bound and CL signal was generated by catalysed substrates. b Microarray layout. Capture probes 
were spotted in triplicate in col. The sequences of (T)20 were repeated seven times for quality control. c CL detection results of parts of cultivated 
influenza viruses. These cultivated influenza virus strains of influenza virus were derived from the National Institutes for Food and Drug Control and 
CDC of Zhejiang Province. The results showed that the microarray was able to distinguish the subtypes of avian influenza A (H7N9), avian influenza 
A (H5N1), 2009 influenza A (H1N1), seasonal influenza A (H1N1), influenza A (H3N2), and influenza B virus very well
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96-Well Thermal Cycler PCR system (Applied Biosys-
tems, USA) under the following conditions: 30  min at 
50  °C; 2 min at 94  °C; 45 cycles of 20 s at 94  °C, 20 s at 
52 °C, and 20 s at 72 °C; and a final extension of 5 min at 
72 °C.
Hybridization and signal detection
After amplification, the three reaction products derived 
from the same template were mixed into one tube (10 µl 
each). After 5 min of denaturation at 95 °C, the mixture 
was immediately placed on ice 5  min and then mixed 
with 5  μl of hybridization buffer (8×  SSC, 0.6  % SDS, 
10 % formylamine, and 10× Denhardt). A total of 10 μl 
of hybridization mixture was hybridized on the microar-
ray for 1 h at 45 °C as described (Zhang et al. 2013). Then, 
the chip was washed for 30 s each with 1× SSC and 0.2 % 
SDS, 0.2×  SSC, and 0.1×  SSC at room temperature. 
Then the chip was incubated with 15 μl of streptavidin-
horseradish peroxidase (Str-HRP, SIGMA) for 25  min 
at 37  °C. Subsequently, the chip was washed with PBST 
(phosphate buffer, 0.05  % Tween 20) 10  s at room tem-
perature. Finally, 10 μL of pre-mixed CL HRP substrate 
luminol solution and H2O2 (Millipore Corporation, USA) 
was added to the chip and immediately detected with a 
micro-light level imaging system (developed in-house, 
China Patent Application No. 201310013267.X).
Specificity and sensitivity
The specificity of this microarray was evaluated using 
40 cultivated influenza A and B virus strains which were 
derived from CDC of Zhejiang Province and the National 
Institutes for Food and Drug Control. The genotype of 
these cultivated influenza viruses had been determined 
and cultivated at these two institutions. Influenza A and 
B Nucleic Acid Detection Kits (PCR-fluorescent probe) 
(Shenzhen Puruikang Biotech Co., Ltd.) which gener-
ally detected influenza A viruses and influenza B viruses, 
were used to compare results. A panel of non-influenza 
respiratory viruses, which include parainfluenza virus, 
adenovirus AD3, AD4, AD30, AD40, measles virus, 
mumps virus, and respiratory syncytial viruses HK6 
and B, were also used to determine the specificity of the 
microarray.
In order to evaluate the sensitivity of this microarray 
in the detection of various subtypes of influenza virus, 
the RNA extraction of cultivated virus strains of 5 sub-
types of influenza A virus and influenza B virus were seri-
ally diluted in tenfold increments and detected using the 
microarray. Influenza A and B Nucleic Acid Detection 
Kits (PCR-fluorescent probe) (Shenzhen Puruikang Bio-
tech Co., Ltd.) were also used to compare results. They 
amplify the conserved M gene of influenza A viruses and 
the NS gene region of influenza B viruses.
Clinical samples
To investigate the efficiency of clinical testing, 66 clinical 
swab samples were collected from the 307th Hospital of 
the Chinese People’s Liberation Army. Total RNAs were 
extracted using a TIANamp Virus RNA Kit as described 
in the manufacturer’s protocol. Then the clinical swab 
samples were detected using a microarray and veri-
fied using four different kinds of real-time RT-PCR kits. 
These real-time RT-PCR kits included a 2009 Influenza 
A Virus (H1N1) Nucleic Acid Detection Kit (PCR-fluo-
rescent probe) (Shenzhen Puruikang Biotech Co., Ltd.), 
2009 Influenza A Virus (H1N1) Nucleic Acid Detection 
Kit (PCR-fluorescent probe) (DAAN Gene Co., Ltd.), 
Seasonal Influenza A Virus (H3) Nucleic Acid Detec-
tion Kit (PCR-Fluorescent probe) (DAAN Gene Co., 
Ltd.), and Diagnosis Kit for H7N9 Avian Influenza Virus 
RNA (PCR-fluorescent probe) (Shenzhen Puruikang Bio-
tech Co., Ltd.). These real-time RT-PCR kits identified 
and determined the concentration of HA gene of 2009 
influenza A (H1N1), NA gene of 2009 Influenza A Virus 
(H1N1), influenza A (H3N2), and avian influenza H7N9 





In this assay, a total of 40 cultivated influenza virus strains 
were tested to determine the specificity of this micro-
array. The types or subtypes of these strains included 6 
avian influenza A (H7N9), 6 influenza A (H3N2), 4 sea-
sonal influenza A (H1N1), 2 2009 influenza A (H1N1), 
18 avian influenza A (H5N1), and 4 influenza B virus. 
The results showed that one strain of H3N2 was mixed 
with H1N1, one strain of H5N1 was mixed with H1N1, 
another strain of H5N1 was mixed with H3N2, one strain 
of influenza B was mixed with H1N1, and one strain of 
H3N2 did not subtype because of its low concentration. 
The four mixed samples were confirmed by amplify-
ing the M gene (for influenza A viruses) or NS gene (for 
influenza B viruses) of influenza using universal primers 
of influenza A and B viruses (Table  1) respectively and 
ligating the amplifications into the T-vector which were 
subsequently Sanger sequenced (data not shown). The 
Sanger sequencing results were coordinated to that of 
a microarray (results not shown). The results indicated 
that the microarray was able to distinguish these sub-
types of influenza A and B viruses (Fig. 1c). There were 
no cross-signals between various influenza A virus sub-
types, and the microarray simultaneously detected mixed 
subtypes in some mixed samples. Furthermore, because 
we observed a lower signal for H5N1 than the other sub-
types with the general influenza A primers targeting the 
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M gene (Fig.  1c), we investigated the number of mis-
matches of our probes to the H5N1 strains used here. 
Overall, there were 0, 1 and 1 mismatches in the forward 
primer, probe and reverse primer regions. In comparison, 
the suggested universal WHO primers (WHO 2009) also 
targeting the M gene have 1, 0 and 1 mismatches against 
the same strains in the forward primer, probe and reverse 
primer regions, respectively. In addition, the negative 
microarray results of these common respiratory viruses 
also demonstrated the specificity of this assay (Fig.  2). 
The information and detection results of the forty influ-
enza virus strains are shown in Table 3.
The limit of detection of the microarray
To assess sensitivity, the microarray detection methods 
were compared to real-time RT-PCR. Results showed 
that the microarray have similar (for PH1N1) or tenfold 
higher limit of detection (LOD) (to the other subtypes 
of influenza A virus and influenza B virus) than the ref-
erenced real-time RT-PCR method. The LOD of general 
influenza A virus detection was lower than the LOD of 
genotype detection. The LOD for the two comparator 
real-time PCR assays was 1 × 103 PFU/ml, so the LOD of 
the microarray was 1 × 103–10 × 103 PFU/ml. The com-
parative results of LOD of avian influenza A (H7N9) are 
shown in Fig. 3. The comparative results of LOD of other 
influenza viruses are shown in Table 4.
Detection of subtypes of cultivated virus and clinical positive 
swab samples
Sixty-six clinical swab samples were detected by micro-
array. Results indicated that 25 of the samples were 2009 
influenza A (H1N1), 3 were influenza A (H3N2), 26 were 
influenza A, 1 contained both 2009 influenza A (H1N1) 
and influenza A (H3N2), and 11 were negative. Four dif-
ferent real-time PCR influenza genotyping kits served as 
reference methods. Results are shown in Table  5. Some 
samples that were only shown to contain only influenza A 
by microarray were confirmed to have specific subtypes 
using real-time PCR kits. This may be because the micro-
arrays are less sensitive than real-time PCR kits. The 
results showed that microarray always failed to deter-
mine the subtypes of samples when the CT value of real-
time RT-PCR exceeded 31. However, general detection 
of influenza A virus is possible even when the CT val-
ues were as high as 39. Consequently, general detection 
of influenza A virus was more sensitive than genotyping 
and detection of influenza A virus subtypes.
The statistical data of 66 clinical throat swab samples 
are shown in Table  6. The sensitivity, specificity, posi-
tive predictive values, and negative predicative values of 
microarray were 91.1, 60.0, 92.7, and 54.5 % those of the 
corresponding PCR kits. Furthermore, the value of gen-
otyping for positive samples using this microarray was 
53.6  %. The low specificity was attributable to the fact 
that there were four samples shown to contain influenza 
A by microarray and whose subtypes were not confirmed 
using real-time PCR kits. The results for these four speci-
mens may be attributable to the low viral load or perhaps 
the influenza viruses were from subtypes not included in 
the microarray or real-time PCR kits. The low negative 
predicative values were attributable to the low sensitiv-
ity of the microarray relative to real-time PCR kits, which 
has been confirmed in cultivated influenza virus strains.
Discussion
Influenza A virus can infect various host species, and the 
greatest diversity of subtypes is found in wildfowl. The 
influenza virus genome comprises 8 independent RNA 
strands, so it can easily undergo antigenic drift, anti-
genic shift, and reassortment, which allows it to cause 
major pandemics (Labella and Merel 2013). Over the past 
100  years, four subtypes of influenza A virus have had 
an enormous impact on human beings, H1N1, H3N2, 
H2N2, and H5N1. Data from the American Center for 
Disease Control and Prevention have shown the influ-
enza B virus to account for only 14 % of cases from Octo-
ber 2011 to May 2012 (CDC 2012). In 2013, there was 
a sudden human avian influenza A (H7N9) outbreak, 
inducing great panic in China. Clinical data suggested 
that H7N9 caused pneumonia with various degrees of 
severity, acute lung injury, acute respiratory distress syn-
drome, and even multiple organ failure. Increased con-
centrations of C reactive protein were found to be closely 
associated with mortality (Lu et  al. 2014). According to 
Fig. 2 Detection of non-influenza respiratory viruses. The negative 
microarray results of these common respiratory viruses also demon-
strated the specificity of this assay
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published reports, the median age of patients who died 
of H7N9 was significantly higher than that of patients 
with nonfatal cases. Patients found to have increased risk 
of death upon admission were subjected to cheat imag-
ing and found to have either bilateral lung inflammation 
or pulmonary consolidation. There were found to be 
Table 3 Statistics and detection of 40 influenza virus stains
a Six avian influenza A (H7N9) viruses were collected from Centers for Disease Control (CDC) of Zhejiang Province. The others were collected from the National 
Institutes for Food and Drug Control
b The results of microarray were corresponding combination signals of microarray probes. All results were obtained in 2/2 experiments
c The real-time PCR reagents for influenza A and B viruses were influenza A virus and B virus Nucleic Acid Detection Kits (PCR-fluorescent probe) (Shenzhen Puruikang 
Biotech Co., Ltd.)
Strain informationsa Microarray resultsb Real time PCR resultsc Cultivate results
Clinical isolated strain H7 + N9 + A 20.3/22.2 H7N9
Clinical isolated strain H7 + N9 + A 20.3/28.7 H7N9
Clinical isolated strain H7 + N9 + A 18.4/26 H7N9
Clinical isolated strain H7 + N9 + A 21.1/28.1 H7N9
Clinical isolated strain H7 + N9 + A 26/28.3 H7N9
Clinical isolated strain H7 + N9 + A 33/33 H7N9
BV/GuangdongLuohu/15/2007 B 20.33 B
B/Jiangxixinjian/39/2008 B + H1N1 + A 21.4 B
BY/FujianXinluo/54/2006 B 20.25 B
B/Tianjin/2/2001 B 18.06 B
A/Hiroshima/52/2005 H3N2 + A 19.3 H3N2
A3/Yunnan/1145/2005 H3N2 + A 19.3 H3N2
A3/Hanfang/359/1995 H3N2 + A 21.37 H3N2
A/Wisconsin/62/2005 H3N2 + A 19.91 H3N2
A/Minfang/1411/2002 A – H3N2
A3/Shenzhen/1/1999 H1N1 + H3N2 + A 21.22 H3N2
A/Newcaledonia/20/99 H1N1 + A 19.54 H1N1
A1/HubeiHongshan/53/2005 H1N1 + A 19.52 H1N1
A/Guangdongluohu/219/2006 H1N1 + A 20 H1N1
A1/Hufang/7/1999 H1N1 + A 18.96 H1N1
A/Beijin/SWL5/09 PH1N1 + A 20.42 H1N1/2009
A/Califonia/07/09 PH1N1 + A 20.84 H1N1/2009
A/Sichuan/1/2006 A1 H5N1 + A 30.89 H5N1
A/Sichuan/1/2006 A2 H5N1 + A 30.64 H5N1
A/Sichuan/2/2006 B H5N1 + A 28.82 H5N1
A/Sichuan/3/06 H5N1 + A 28.32 H5N1
A/XJ/1/06 M1 H5N1 + A 26.93 H5N1
A/XJ/1/06 M2 H5N1 + A 26.55 H5N1
A/XJ/1/2006 L H5N1 + A 27.04 H5N1
A/Anhui/1/2006 C H5N1 + A 27.04 H5N1
Clinical isolated strain H5N1 +H1N1 + A 28.3 H5N1
Clinical isolated strain H5N1 + A 28.24 H5N1
Clinical isolated strain H5N1 +H3N2 + A 25.59 H5N1
Clinical isolated strain H5N1 + A 27.46 H5N1
Clinical isolated strain H5N1 + A 32.19 H5N1
Clinical isolated strain H5N1 + A 27.7 H5N1
Clinical isolated strain H5N1 + A 32.08 H5N1
Clinical isolated strain H5N1 + A 28.59 H5N1
A/GX/LA/13/04 K1 H5N1 + A 28.84 H5N1
A/GX/LA/13/04 K2 H5N1 + A 29.2 H5N1
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significant levels of lymphopenia and decreases in oxy-
genation index in patients who eventually died (Ji et  al. 
2014).
Since October 2013, the strains of influenza A circulat-
ing in China have been completely resistant to amanta-
dine drugs. Some of the 2009 influenza A (H1N1) strains 
have been found to be associated with lower suscepti-
bility to NA inhibitor as indicated by weekly monitor-
ing. Many studies have shown that the severity of the 
infection is more likely to be reduced if an NA inhibi-
tor is administered within 48 h of the onset of influenza 
symptoms than when it is administered later (Hayden 
et al. 1997; McGeer et al. 2007; Monto et al. 1999). Vac-
cination is another effective way to prevent the spread 
of pandemic virus and reduce the severity of the disease 
(Luke and Subbarao 2006). Synthetic DNA vaccines and 
virus-like-particle vaccines have been developed for 
avian influenza A (H7N9) (Dormitzer et  al. 2013; Fries 
et al. 2013; Klausberger et al. 2014; Smith et al. 2013; Yan 
et  al. 2014). Because vaccine strains match circulating 
strains closely, it is important to rapidly and continuously 
monitor of epidemic influenza virus strains to determine 
which strains should be covered by seasonal influenza 
vaccinations (Bandt et al. 2012; Luke and Subbarao 2006; 
Subbarao et  al. 2006). Rapid and accurate diagnosis of 
avian influenza A (H7N9) and other common influenza 
viruses is essential to improving clinical patient manage-
ment and epidemiological investigation.
Currently, real-time RT-PCR is the most widely used 
molecular diagnostic approach to the detection of influ-
enza virus in clinical settings (Choi et al. 2013; Dawood 
et  al. 2009; Gao et  al. 2013a; Hackett et  al. 2014; Poon 
et  al. 2009; Templeton et  al. 2004). Although the real-
time RT-PCR approach is generally more sensitive 
than microarray, only a few subtypes of influenza can 
be detected in the same reaction (Choi et al. 2013; Kuo 
et  al. 2014). Microarrays are high-throughput and can 
be used to simultaneously detect several or even all the 
Fig. 3 LOD of detection of avian influenza A (H7N9). The RNA extraction of avian influenza (H7N9) was serially diluted in tenfold increments and 
detected using this microarray and influenza A virus Nucleic Acid Detection Kits (PCR-fluorescent probe) (Shenzhen Puruikang Biotech Co., Ltd.). The 
microarray possessed a tenfold higher LOD to avian influenza A (H7N9) than the real-time RT-PCR method
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subtypes of influenza (Gall et  al. 2009; Han et  al. 2008; 
Heil et  al. 2010; Ryabinin et  al. 2011). However, tradi-
tional microarray detection requires expensive fluo-
rescence scanners, which limit its use. Analytical CL is 
a versatile, sensitive method of detection with a wide 
range of uses, including enzyme-linked immunosorbent 
assays (Liu et al. 2012; Maiolini et al. 2013), lateral flow 
immunoassays (Maiolini et  al. 2013; Wolter et  al. 2008; 
Wutz et  al. 2013), flow-through hybridization assays 
(Hommatsu et al. 2013), capillary electrophoresis (Jiang 
et  al. 2013), flow injection CL analysis (Tan and Song 
2013), and magnetic bead-based DNA hybridization 
assays (Li and He 2009). This is the first paper to subtype 
influenza viruses using a chemiluminescent oligonucleo-
tide microarray. In this assay, a sensitive CL method that 
relies on horseradish peroxidase was used to catalyze 
the luminol-H2O2 for a conventional oligonucleotide 
microarray. A proprietary potable CL imaging system 
was established. The imaging system was based on CCD 
camera imaging technology and equipped with a power 
supply suitable for portable use (China Patent Applica-
tion No. 201310013267.X). Furthermore, other commer-
cial CL imagers based on CCD imaging technology (e.g. 
Amersham Imager 600, GE Healthcare Life Sciences) 
could also be used for this CL microarray. The new CL 
imager had a lower cost and a much faster detection 
speed than our previous visual microarray system which 
was based on quantum dot-catalyzed silver deposition. 
The cost of this CL imaging microarray was also lower 
than that of our previous fluorescence based microarray 
system (Zhang et al. 2013).
This assay was designed based on the following ideas: 
(1) priority was given to the detection avian influenza 
A (H7N9) (H7 and N9 were detected simultaneously). 
(2) Other than avian influenza A (H7N9), only the most 
common subtypes of influenza virus were detected by 
genotyping in this microarray. (3) Other than genotyp-
ing detection, the microarray also universal detected the 
more conservative M gene of influenza A viruses and 
NS gene of influenza B viruses to extend the range of the 
application. (4) One-step RT-PCR amplification was used 
to reduce the length of the experimental procedure and 
so reduce the risk of contamination. (5) Human-derived 
primers and probes served as internal standards; they 
were added to all the amplification reactions to moni-
tor extraction of clinical samples, RT-PCR amplification, 
and microarray hybridization. (6) Low-cost CL imaging 
technology was used for detection in the microarray. This 
may allow this system to be used on a large scale.
A low-density CL oligonucleotide microarray was 
developed for genotyping detection of the newest avian 
influenza A (H7N9), avian influenza A (H5N1), 2009 
influenza A (H1N1), seasonal influenza A (H1N1), and 
influenza A (H3N2). Influenza A viruses and influenza B 
viruses were also generally detected using this microar-
ray. The microarray kits used here were capable of rapid, 
Table 4 The limit of detection of the microarray
The real-time PCR reagents for influenza A and B viruses were influenza A virus and B virus Nucleic Acid Detection Kits (PCR-fluorescent probe) (Shenzhen 
Puruikang Biotech Co., Ltd.). The microarray possessed similar or tenfold higher LOD than the real-time RT-PCR method. The reference PFU given for the PCR kits are 
approximated 1 × 103 PFU/ml given by the manufacturers and vary between the kits
Virus Dilution Micorarray results Real time PCR results (Ct) Virus Dilution Micorarray results Real time PCR results (Ct)
H7N9 Original H7 + N9 + A 23.7 H1N1 Original H1N1 + A 14.97
10−1 H7 + N9 + A 28.22 10−1 H1N1 + A 17.49
10−2 H7 + N9 + A 31.79 10−2 H1N1 + A 21.55
10−3 – 36.69 10−3 H1N1 + A 26.21
10−4 – – 10−4 H1N1 + A 30.78
10−5 – – 10−5 A 33.79
H5N1 Original H5N1 + A 22.55 H3N2 Original H3N2 + A 15.7
10−1 H5N1 + A 27.98 10−1 H3N2 + A 18.68
10−2 – 35.99 10−2 H3N2 + A 22.72
10−3 – – 10−3 H3N2 + A 27.08
10−4 – – 10−4 H3N2 + A 31.01
10−5 – – 10−5 – 33.29
PH1N1 Original PH1N1 + A 16.24 B Original B 18.41
10−1 PH1N1 + A 19.41 10−1 B 22.53
10−2 PH1N1 + A 23.3 10−2 B 26.92
10−3 PH1N1 + A 27.52 10−3 B 31.01
10−4 PH1N1 + A 32.72 10−4 – 36.56
10−5 – – 10−5 – –
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high-throughput, highly accurate readings, and the entire 
detection time from sample extraction to the produc-
tion of genotyping results was 6–8 h. Six avian influenza 
A (H7N9) culture viruses and thirty-four other influenza 
culture viruses served as positive references to confirm 
the specificity and sensitivity of the microarray. Some 
non-influenza respiratory viruses were also tested using 
the microarray to further confirm this specificity. All the 
results showed that the microarray accurately detected 
the genotypes of these influenza viruses and of some 
mixed influenza strains. The LOD of genotyping and uni-
versal detection of influenza viruses were similar to or 
ten-fold higher than reference values for influenza real-
time RT-PCR kits. Sixty-six clinical swab samples were 
Table 5 The genotyping results of 66 clinical throat swab samples
a The real-time PCR reference reagent of H1 was a 2009 Influenza A Virus (H1N1) Nucleic Acid Detection Kit (PCR-Fluorescent probe) (Shenzhen Puruikang Biotech Co., 
Ltd.)
b The real-time PCR reference reagent of N1 was 2009 Influenza A Virus (H1N1) Nucleic Acid Detection Kit (PCR-fluorescent probe) (DAAN Gene Co., Ltd.)
c The real time PCR reference reagent of H3 was Seasonal Influenza A Virus (H3) Nucleic Acid Detection Kit (PCR-Fluorescent probe) (DAAN Gene Co., Ltd.)
d  The real time PCR reference reagent of H7 was Diagnosis Kit for H7N9 Avian Influenza Virus RNA (PCR-fluorescent probe) (Shenzhen Puruikang Biotech Co., Ltd.)
Results indicated that 25 of the samples were 2009 influenza A (H1N1), 3 were influenza A (H3N2), 26 were influenza A, 1 contained both 2009 influenza A (H1N1) 
and influenza A (H3N2), and 11 were negative. The results showed that microarray always failed to determine the subtypes of samples when the CT value of real-time 
RT-PCR exceeded 31. However, general detection of influenza A virus is possible even when the CT values were as high as 39. Consequently, general detection of 
influenza A virus was more sensitive than genotyping and detection of influenza A virus subtypes
No. H1a (Ct) N1b (Ct) H3c (Ct) H7d (Ct) Microarray results No. H1 (Ct) N1 (Ct) H3 (Ct) H7 (Ct) Microarray results
1 27.79 29.59 – – PH1N1 + A 34 32.71 33.01 – – A
2 – – 39.20 – A 35 21.11 21.14 – – PH1N1 + A
3 – – 34.26 – A 36 21.08 22.59 – – PH1N1 + A
4 26.04 29.06 – – PH1N1 + A 37 29.17 31.4 – – PH1N1 + A
5 – – 37.23 – A 38 – – 27.30 – H3N2 + A
6 – – 32.57 – H3N2 + A 39 – – – – –
7 23.23 25.41 – – PH1N1 + A 40 30.06 31.83 – – PH1N1 + A
8 26.74 28.78 – – PH1N1 + A 41 25.34 21.22 – – PH1N1 + A
9 – – 31.15 – A 42 32.88 34.43 – – A
10 21.06 22.65 – – PH1N1 + A 43 20.37 21.41 – – PH1N1 + A
11 17.43 19.43 – – PH1N1 + A 44 26.09 26.3 – – PH1N1 + A
12 – – 31.91 – H3N2 + A 45 – – 31.53 – A
13 – 30.29 – – A 46 32.59 33.09 – – –
14 – – – – A 47 26.88 27.87 – – PH1N1 + A
15 25.79 26.51 – – PH1N1 + A 48 – – 38.43 – A
16 35.71 36.76 – – – 49 – – – – –
17 30.20 33.15 – – PH1N1 + A 50 31.75 31.37 – – PH1N1 + A
18 28.48 28.42 – – PH1N1 + A 51 – – 35.09 – A
19 27.42 26.41 33.61 – PH1N1 + A 52 30.63 31.68 – – A
20 28.91 31.06 30.64 – PH1N1 + H3N2 + A 53 35.10 35.15 – – –
21 27.97 29.61 – – PH1N1 + A 54 – – 36.08 – A
22 – – – – A 55 – – 38.69 – A
23 – – – – – 56 – – – – A
24 27.43 27.58 – – PH1N1 + A 57 – – – – –
25 – – – – A 58 – – – – –
26 26.63 28.38 – – PH1N1 + A 59 – – 33.94 – A
27 28.53 30 – – PH1N1 + A 60 – – – – –
28 35.71 35.16 – – – 61 27.38 27.57 – – PH1N1 + A
29 – – 38.22 – A 62 32.67 35.06 – – A
30 23.68 26.25 – – PH1N1 + A 63 24.28 21.9 – – PH1N1 + A
31 33.90 35.31 – – A 64 33.17 32.83 – – –
32 33.76 34.12 – – A 65 32.53 32.64 – – A
33 33.82 35.42 – – A 66 30.55 31.76 – – A
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assessed using microarray to determine the efficiency 
of this type of clinical testing and epidemiology. Results 
showed that the specificity and sensitivity of the microar-
ray met the needs of clinical and epidemiological studies 
of the influenza virus.
This method has some limitations. RT-PCR amplification 
was here divided into three groups to amplify different sub-
types of influenza viruses. This complicated the operation. 
However, reducing the number of amplification systems 
(increasing the number of primers in one amplification sys-
tem) may have decreased sensitivity. Here, 11 pairs of prim-
ers were divided into three groups of amplification systems, 
and the LOD of this microarray was still ten times higher 
than that of the real-time PCR kits used for reference (the 
sensitivity of 2009 influenza A virus was similar to that of 
real-time RT-PCR kit). The 66 clinical swab samples were 
detected and microarray failed to show subtypes of samples 
when the CT value of real-time RT-PCR more than 32. How-
ever, general detection of influenza A virus was still positive 
even when the CT values were as high as 39. Consequently, 
the sensitivity of this CL detection strategy and microarray 
could be improved by further optimization. Moreover, avian 
influenza A (H7N9) and (H5N1) were not actually compara-
tively tested using the developed microarray and PCR assays 
due to the deficiency of clinical specimens.
Furthermore, the use of this strategy was restricted 
because of the limitations of detection for only novel avian 
influenza A (H7N9) and some of the most common human 
influenza viruses. The other influenza A subtypes such as 
H5N6 and H9N2, can not be typed. Thus, sequencing or 
other diagnostic methods are still needed to determine the 
exact subtypes of those influenza A viruses.
Conclusions
A reliable CL detection oligonucleotide microar-
ray was developed to genotype and detected avian 
influenza A (H7N9), avian influenza A (H5N1), 2009 
influenza A (H1N1), seasonal influenza A (H1N1), and 
seasonal influenza A (H3N2). Influenza A viruses and 
influenza B viruses were also generally detected using 
this microarray. The results of detection of 40 culti-
vated influenza virus strains showed the microarray 
to be able to distinguish the subtypes of these influ-
enza viruses very well. The microarray possessed simi-
lar or tenfold higher LOD than the real-time RT-PCR 
method. Sixty-six clinical swab samples were detected 
by microarray and verified using real-time RT-PCR to 
evaluate the efficiency of this microarray for clinical 
testing.
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Table 6 The statistics of 66 clinical throat swab samples
The sensitivity of microarray compared to real-time PCR was 91.1 %
The specificity of microarray compared to real-time PCR was 60.0 %
The positive predictive values of microarray compared to real-time PCR was 
92.7 %
The negative predicative values of microarray compared to real-time PCR was 
54.5 %
The diagnose accordance rate of microarray compared to real-time PCR was 
86.4 %
The percent of genotyping for positive sample of microarray was 53.6 %
Microarray Real‑time PCR
Positive Negative
Positive (genotype) 51 (30) 4 (0)
Negative (genotype) 5 (0) 6 (0)
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